Video

Taking a Closer Look at PCSK9 Part 2

Author(s):

If the new class of drugs are as effective as they appear to be in early studies, it could have a drastic affect on how patients with cardiac issues are treated in the future.

If the new class of drugs are as effective as they appear to be in early studies, it could have a drastic affect on how patients with cardiac issues are treated in the future.

Jennifer Robinson, MD, MPH, from the University of Iowa discussed how the landscape could change with these new drugs and what it could mean to overall patient care at the American College of Cardiology's Annual Scientific Sessions and Expo in San Diego.

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
A. Sidney Barritt, MD | Credit: UNC School of Medicine
© 2024 MJH Life Sciences

All rights reserved.